Education
About Us
Working with TipRanks
Follow Us
Oculis Holding (OCS)
NASDAQ:OCS
OCS Stock Chart & Stats
$24.86
$0.20(1.10%)
At close: 4:00 PM EST
$24.86
$0.20(1.10%)
Day’s Range― - ―
52-Week Range$14.00 - $30.68
Previous CloseN/A
Volume95.89K
Average Volume (3M)58.01K
Market Cap
$1.41B
Enterprise Value$1.03B
Total Cash (Recent Filing)$213.25M
Total Debt (Recent Filing)$2.32M
Price to Earnings (P/E)―
Beta0.34
Next Earnings
May 07, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.53
Shares Outstanding57,169,476
10 Day Avg. Volume127,612
30 Day Avg. Volume58,014
Financial Highlights & Ratios
PEG Ratio0.60
Price to Book (P/B)4.22
Price to Sales (P/S)0.00
P/FCF Ratio-13.27
Enterprise Value/Market Cap0.73
Enterprise Value/Revenue2.04K
Enterprise Value/Gross Profit-71.50
Enterprise Value/Ebitda-10.81
Forecast
1Y Price Target
$47.25Price Target Upside90.06% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.75
Revenue Forecast (FY)$4.71M
Bulls Say, Bears Say
Bulls Say
Clinical TrialsPositive pivotal DIAMOND trial results for OCS-01 could enable a New Drug Application filing for a first-in-class topical treatment for diabetic macular edema, creating a clear path to market.
Market OpportunityPrivosegtor's proof-of-concept vision improvements and the absence of approved neuroprotective treatments position it to capture a first-mover commercial advantage in optic neuritis and related neuro-ophthalmic conditions.
Regulatory PathwayFDA Breakthrough Therapy designation for privosegtor can allow close regulatory engagement and expedited review options, potentially shortening the path to approval if registrational trials confirm benefit.
Bears Say
Dilution RiskHigh cash burn relative to available cash can force equity raises that risk shareholder dilution and weigh on the stock.
Financial PerformanceA sizable annual net loss reflects significant cash burn that could increase pressure on liquidity and the need for external funding.
Operational RiskA limited cash runway raises the risk that trial programs could face delays or scaling back if financing is not secured, threatening development timelines.
Oculis Holding News
OCS FAQ
What was Oculis Holding’s price range in the past 12 months?
Oculis Holding lowest stock price was $14.00 and its highest was $30.68 in the past 12 months.
What is Oculis Holding’s market cap?
Oculis Holding’s market cap is $1.41B.
When is Oculis Holding’s upcoming earnings report date?
Oculis Holding’s upcoming earnings report date is May 07, 2026 which is in 44 days.
How were Oculis Holding’s earnings last quarter?
Oculis Holding released its earnings results on Mar 03, 2026. The company reported -$0.533 earnings per share for the quarter, missing the consensus estimate of -$0.481 by -$0.052.
Is Oculis Holding overvalued?
According to Wall Street analysts Oculis Holding’s price is currently Undervalued.
Does Oculis Holding pay dividends?
Oculis Holding does not currently pay dividends.
What is Oculis Holding’s EPS estimate?
Oculis Holding’s EPS estimate is -0.51.
How many shares outstanding does Oculis Holding have?
Oculis Holding has 57,169,476 shares outstanding.
What happened to Oculis Holding’s price movement after its last earnings report?
Oculis Holding reported an EPS of -$0.533 in its last earnings report, missing expectations of -$0.481. Following the earnings report the stock price went up 0.544%.
Which hedge fund is a major shareholder of Oculis Holding?
Currently, no hedge funds are holding shares in OCS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oculis Holding Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$47.25 (90.06% Upside)
$47.25 (90.06% Upside)
Hedge Fund Trend
Increased
By 611.2K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
53.49%
12-Months-Change
Fundamentals
Return on Equity
-62.46%
Trailing 12-Months
Asset Growth
124.27%
Trailing 12-Months
Company Description
Oculis Holding
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. The company's lead candidate is OCS-01, a topical dexamethasone formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for keratoconjunctivitis sicca, or dry eye disease; and OCS-05, a novel neuroprotective agent for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.
OCS Stock 12 Month Forecast
Average Price Target
$47.25
▲(90.06% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Spyre Therapeutics
―
Praxis Precision Medicines
―
ARS Pharmaceuticals
―
Upstream Bio, Inc.
―
Ownership Overview
―
Insiders
0.67% Mutual Funds
25.27% Other Institutional Investors
73.79% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---